183 related articles for article (PubMed ID: 21648209)
1. Trabectedin and ovarian cancer: statistical trickery.
Prescrire Int; 2011 Apr; 20(115):93. PubMed ID: 21648209
[No Abstract] [Full Text] [Related]
2. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
5. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
Boccia SM; Sassu CM; Ergasti R; Vertechy L; Apostol AI; Palluzzi E; Fagotti A; Scambia G; Marchetti C
Drug Des Devel Ther; 2024; 18():2021-2032. PubMed ID: 38863768
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: Supportive care strategies and safety profile.
Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
López-Guerrero JA; Romero I; Poveda A
Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin.
Chuk MK; Balis FM; Fox E
Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
[No Abstract] [Full Text] [Related]
9. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A
Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer.
Clare J
Future Oncol; 2013 Dec; 9(12 Suppl):1. PubMed ID: 24195522
[No Abstract] [Full Text] [Related]
11. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin in ovarian cancer: could we expect more?
Sessa C; D'Incalci M
Ann Oncol; 2011 Jan; 22(1):7-8. PubMed ID: 21059638
[No Abstract] [Full Text] [Related]
15. Trabectedin and ovarian cancer (continued).
Prescrire Int; 2011 Oct; 20(120):249-50. PubMed ID: 21970099
[No Abstract] [Full Text] [Related]
16. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
Khokhlova SV; Cherkasova MV; Orel NF; Limareva SV; Bazaeva IIa; Gorbunova VA
Vestn Ross Akad Med Nauk; 2013; (11):115-21. PubMed ID: 24640740
[TBL] [Abstract][Full Text] [Related]
17. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Adam JP; Boumedien F; Letarte N; Provencher D
Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
[No Abstract] [Full Text] [Related]
19. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
